ABSCINT: Advancing Precision Oncology with PET Imaging
ABSCINT is a pioneering biotechnology company specializing in the development of advanced imaging solutions for precision oncology. The company focuses on molecular imaging, particularly using Positron Emission Tomography (PET) tracers, to enhance cancer diagnostics and treatment monitoring. Its flagship solution is an innovative anti-HER2 PET tracer, designed to provide whole-body imaging of HER2-positive cancers.
HER2 (human epidermal growth factor receptor 2) is a key biomarker in breast and gastric cancers. Traditional methods of HER2 assessment rely on biopsies, which can be invasive and fail to capture tumor heterogeneity. ABSCINT’s PET imaging solution overcomes these limitations by offering a non-invasive, whole-body view of HER2 expression, enabling better treatment decisions.
By using radio-labeled single-domain antibodies (sdAbs), ABSCINT’s technology allows for high-contrast imaging with superior precision. This enables physicians to:
Detect HER2-positive tumors across the body.
Monitor tumor heterogeneity and disease progression in real time.
Evaluate treatment response, allowing for timely adjustments in therapy.
Facilitate HER2 reclassification, guiding more personalized treatment strategies.
This imaging innovation is particularly valuable for patients with metastatic or recurrent cancers, where HER2 status may evolve over time. By integrating PET imaging with precision medicine, ABSCINT helps optimize therapeutic choices, leading to better patient outcomes.
As a leader in radio-immunodiagnostics, ABSCINT is driving the future of oncology imaging, ensuring that patients receive more targeted, effective, and personalized cancer treatments. Through continued research and development, the company aims to expand its portfolio of PET tracers to address additional oncological and inflammatory conditions.
